NCT06368167View on ClinicalTrials.gov

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Follicular Lymphoma

Interventions

DRUG

SHR2554

SHR2554

Trial Locations (1)

100142

Peking University Cancer Hospital, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY